Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
Basel, 16 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented major updates on its innovative sequencing by expansion (SBX) technology at the American Society of Human Genetics (ASHG) 2025 Ann
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
09:41am, Wednesday, 15'th Oct 2025
Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.
Wall Street Breakfast Podcast: Papa John's Delivers A Hot Slice
07:49am, Tuesday, 14'th Oct 2025
Papa John's (PZZA) surged nearly 10% after reports of a $64/share takeover bid from Apollo Global. PZZA is up 3% premarket.
Roche, Lilly's blood test for Alzheimer's diagnosis gets US approval
10:47am, Monday, 13'th Oct 2025
Roche Diagnostics said on Monday the U.S. Food and Drug Administration cleared its and partner Eli Lilly's blood test as an aid in the initial assessment for Alzheimer's disease.
Rules out Alzheimer's pathology in early stages to enhance diagnostic pathway efficiency Provides new opportunity to broaden access and improve referral quality Features as part of Roche's growing po
Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types
01:05am, Monday, 13'th Oct 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will present more than 30 abstracts across more than 10 cance
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
01:00am, Monday, 13'th Oct 2025
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology (E
BALA CYNWYD, Pa., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
02:16pm, Monday, 06'th Oct 2025
Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
01:29pm, Monday, 06'th Oct 2025
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of
Advanz Pharma Holdco Limited and Alvotech announced that the European Medicines Agency has accepted a Marketing Authorization Application for AVT23, a proposed biosimilar to Xolair®? . Alvotech
Basel, 6 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), in collaboration with KlinRisk, Inc., has received the CE-mark for the first AI-based risk stratification tool to assess progressive decline
FDA approves Roche's Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
01:05am, Friday, 03'rd Oct 2025
Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizu
Change in the Roche Board of Directors
01:00am, Friday, 03'rd Oct 2025
Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Dr. Claudia Süssmuth Dyckerhoff has decided not to stand for re-election as a member of the Roche Board of Directors at
